All Products are stable to be shipped at room temperature, unless otherwise specified.
| Pack Size | Quantity | Price (USD) | Sub Total |
|---|---|---|---|
| .5mg | $ 175.00 | 0.0 | |
| 2.5mg | $ 815.00 | 0.0 | |
| 5mg | $ 1400.00 | 0.0 | |
| Exact Weight Packaging | $ 145.00 | 0.0 | |
| Total | $ 0.0 | ||
Product successfully added to cart.
- Request another packsize ? Click here.
- Inventory Status : Pending QC
- Ships On :
A115606
Bulk Order Request for A115606
Product Description
| Catalogue Number | A115606 |
| Chemical Name | Acalabrutinib-d3 |
| Synonyms | 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide-d3; |
| Alternate CAS # | 1420477-60-6 |
| Molecular Formula | C₂₆H₂₀D₃N₇O₂ |
| Appearance | Pale Yellow to Light Yellow Solid |
| Melting Point | >129°C (dec.) |
| Molecular Weight | 468.54 |
| Storage | 4°C |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Category | Standards; Isotopic Labeled Analogues; Molecular Biology; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| Applications | Acalabrutinib-d3 is a labeled analog of Acalabrutinib (A115605), which is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). |
| References | Byrd, et al.: (2015). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia."; "AstraZeneca to buy Acerta for blood cancer drug". www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015. |